MCM
KROS icon

Monimus Capital Management’s Keros Therapeutics KROS Stock Holding History

Monimus Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-108,051
Closed -$1.71M – 67
2025
Q3 		$1.71M Buy
108,051
+17,655
+20% +$261K 1.05% 35
2025
Q2 		$1.21M Buy
90,396
+6,341
+8% +$85.6K 0.88% 38
2025
Q1 		$857K Buy
+84,055
New +$976K 0.73% 36

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Monimus Capital Management's KROS Position: Q4 2025 in Review

Monimus Capital Management sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 108,051 shares — an estimated $1.71M sold.

Monimus Capital Management first reported a position in KROS in Q1 2025 and held it in 3 quarters. The position peaked at $1.71M in Q3 2025. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Monimus Capital Management reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Monimus Capital Management sold 108,051 Keros Therapeutics shares in Q4 2025, an estimated $1.71M.
  • Monimus Capital Management first reported a position in Keros Therapeutics in Q1 2025 and held it in 3 quarters.
  • Monimus Capital Management's Keros Therapeutics position peaked at $1.71M in Q3 2025.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Monimus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.